GELS (Gelteq) ROCE %: -24.21% (As of Jun. 2025)


GELS Gelteq Ltd GELS
10 GF Score
Price $0.61
! 3 Warning Signs
View Full Analysis

What is Gelteq ROCE %?

Gelteq GELS -13.03% 10 ROCE % is -24.21% as of Jun. 2025. GuruFocus rates GELS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gelteq's annualized ROCE % for the quarter that ended in Jun. 2025 was -24.21%.

Gelteq  (NAS:GELS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gelteq ROCE % Related Terms

Gelteq ROCE % Historical Data

* Premium members only.

The historical data trend for Gelteq's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq ROCE % Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -5.32 -13.20 -13.95 -15.48 -28.73

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial 0.00 -13.20 -18.49 -29.38 -24.21
GELS
10GF Score
Gelteq Ltd GELS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq ROCE % Calculation

Gelteq's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-3.093/( ( (13.784 - 2.567) + (13.981 - 3.667) )/ 2 )
=-3.093/( (11.217+10.314)/ 2 )
=-3.093/10.7655
=-28.73 %

Gelteq's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-2.692/( ( (15.906 - 3.977) + (13.981 - 3.667) )/ 2 )
=-2.692/( ( 11.929 + 10.314 )/ 2 )
=-2.692/11.1215
=-24.21 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -24.21% mean?
Gelteq (GELS) has a ROCE % of -24.21% as of Jun. 2025.
Is Gelteq's ROCE % too high?
Gelteq's current ROCE % is -24.21%. Overall, Gelteq has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's ROCE % compare to INM and LVRLF?
Gelteq's ROCE % of -24.21% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelteq's current ROCE % is -24.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current ROCE % of -24.21%. The current ROCE % is -24.21%. Gelteq's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Gelteq (GELS), the current ROCE % is -24.21% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
10GF Score

Get the complete analysis for GELS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price